OSRH Stock Overview
A healthcare holding company, develops a portfolio of therapies and healthcare solutions in the United States, Switzerland, and South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
OSR Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.11 |
| 52 Week High | US$13.40 |
| 52 Week Low | US$1.02 |
| Beta | 1.55 |
| 1 Month Change | -18.98% |
| 3 Month Change | -63.49% |
| 1 Year Change | -89.66% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -89.01% |
Recent News & Updates
Recent updates
Shareholder Returns
| OSRH | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -8.3% | 0.4% | 0.8% |
| 1Y | -89.7% | -9.6% | 11.5% |
Return vs Industry: OSRH underperformed the US Biotechs industry which returned -9.6% over the past year.
Return vs Market: OSRH underperformed the US Market which returned 11.5% over the past year.
Price Volatility
| OSRH volatility | |
|---|---|
| OSRH Average Weekly Movement | 49.1% |
| Biotechs Industry Average Movement | 12.1% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in US Market | 17.2% |
| 10% least volatile stocks in US Market | 4.2% |
Stable Share Price: OSRH's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: OSRH's weekly volatility has increased from 36% to 49% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 20 | Peter Hwang | www.osr-holdings.com |
OSR Holdings, Inc., a healthcare holding company, develops a portfolio of therapies and healthcare solutions in the United States, Switzerland, and South Korea. The company develops immunotherapy products, including VXM01, an immuno-oncology candidate for glioblastoma that is in phase 2 clinical trial, as well as preclinical stage products, such as VXM04 to treat mesothelin; VXM06 for the treatment of Wilms Tumor Protein (WT1); VXM08 for Carcinoembryonic antigen (CEA); and VXM10 for PD-L1. It is also developing design-augmented (DA) biologics comprising DRT-102, a clinical-stage asset for spinal fusion; and DRT-101, a pre-clinical stage asset for osteoarthritis.
OSR Holdings, Inc. Fundamentals Summary
| OSRH fundamental statistics | |
|---|---|
| Market cap | US$21.40m |
| Earnings (TTM) | -US$10.45m |
| Revenue (TTM) | n/a |
Is OSRH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OSRH income statement (TTM) | |
|---|---|
| Revenue | -US$148.95k |
| Cost of Revenue | -US$74.52k |
| Gross Profit | -US$74.43k |
| Other Expenses | US$10.37m |
| Earnings | -US$10.45m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.54 |
| Gross Margin | 49.97% |
| Net Profit Margin | 7,014.51% |
| Debt/Equity Ratio | 3.6% |
How did OSRH perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/29 19:09 |
| End of Day Share Price | 2025/05/28 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
OSR Holdings, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.